Health

    Adverum Biotechnologies reports widened full-year loss amidst increased R&D investment

    Article Image

    Adverum Biotechnologies (NASDAQ:ADVM), a company based in Redwood City, California, today reported its financial results for the fourth quarter and full year ended December 31, 2024, revealing a significant increase in its annual loss.

    The company announced a net loss of $40.9 million for the fourth quarter, translating to a loss of $1.96 per share.

    This contributed to a widened full-year loss of $130.9 million, or $6.62 per share, compared to the previous year.

    The company reported annual revenue of $1 million.  

    A key factor in the increased loss was a rise in research and development expenses, which totalled $24.1 million for the three months ending December 31, 2024, up from $15.3 million in the same period of 2023.

    Adverum attributed this increase to higher costs associated with material production, bioanalytics, and increased compensation expenses as the company prepares for Phase 3 clinical trials. 

    Despite the losses, Adverum reported a solid cash position with $125.7 million in cash, cash equivalents, and short-term investments as of December 31, 2024.

    This represents a decrease from the $153.2 million reported at the end of the previous quarter (September 30, 2024) but an increase compared to the $96.5 million held at the end of 2023.

    The company anticipates that its current cash reserves will be sufficient to fund its operations into the second half of 2025.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa